Biotech · Private company · Little Rock, AR, US
Kuria Therapeutics, Inc
Track this companyFree. Adds Kuria Therapeutics, Inc to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards2
- Testing of SCO-116, an NRF2 activator for Fuchs' Dystrophy, in cultured human corneasFiscal year 2026 · $306.8KNIH RePORTER 1R43EY038532-01 · fetched Nov 12, 2026
- IND-enabling studies of KTX-1161, a novel NRF2 activator for corneal endothelial diseaseFiscal year 2025 · $399.9KNIH RePORTER 1R44EY038121-01 · fetched Nov 12, 2026